Royalty Pharma:Tev-'408 目前处于治疗白癜风的 1B 期阶段和乳糜泻的 2a 期阶段

美股速递
Jan 12

Royalty Pharma plc 所关注的候选药物 Tev-'408 目前正同步推进两项临床试验。该药物针对白癜风的治疗研究已进入 1B 期阶段,同时,其在乳糜泻领域的应用研究也已迈入 2a 期临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10